Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in ...

I am writing this from my desk in St. Lucia with my girlfriend patiently waiting, so I will be brief. HROW reported earnings and lowered 2025 guidance to $270M to $280M from $280M+. This is utterly ...

Julie Bowen has spent decades in front of the camera. Her roles in both movies and one of TV’s most beloved sitcoms have meant a lot of exposure to intense lighting and varied effects. But it wasn’t ...

XIIDRA is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) by targeting a source of inflammation. These results reinforce the results from four previous clinical ...

Medicare may cover Xiidra (lifitegrast ophthalmic solution) if you have a plan with prescription drug coverage, such as a Part D plan or a Medicare Advantage (Part C) plan. Xiidra is a brand-name drug ...

Xiidra (lifitegrast) does not have any known interactions with alcohol, other medications, or supplements. However, Xiidra has some health-related interactions. Xiidra is used in adults and children ...

Xiidra (lifitegrast ophthalmic solution) may be safe to use while pregnant or breastfeeding. Your doctor can help you determine whether you should use the drug during this time. If you may be or can ...

Learn how to pronounce player and coach names by listening to the audio of each respective player or coach pronouncing his name NBA.com Staff *This page will continue to be updated as audio content is ...

During a recent Polygon meeting, I realized something: I have no idea how to pronounce Balatro, the name of developer LocalThunk’s incredible roguelite poker game that’s occupied every one of my ...

This article is part of The Salt Lake Tribune’s New to Utah series. For more articles on Utah’s food, culture, history, outdoors and more, sign up for the ...

This summer, Bausch + Lomb unveiled plans to acquire a dry eye disease treatment from Novartis for up to $2.5 billion. Now, the eye health company has closed the deal. The purchase of XIIDRA, a 5% a ...